Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

UCB and Proteros Expand Collaboration

Published: Monday, September 17, 2012
Last Updated: Monday, September 17, 2012
Bookmark and Share
Expansion of the ongoing structural biology collaboration will include additional therapeutic areas.

Since 2007, Proteros has supported discovery programmes for UCB in the area of immunology, by solving complex unpublished protein structures to give UCB scientists insight on how to optimise promising novel compounds. The collaboration has now expanded to include extra programmes/ targets and additionally includes CNS discovery research.

Dr. Neil Weir, Senior Vice President of Discovery, UCB, and Chair of the Innovation Board of the Association of the British Pharmaceutical Industry, remarked, "Collaboration is the foundation of UCB's strategy and we believe advances towards new therapies can be accelerated by combining our expertise in discovery science with a wide network. Proteros have specialist skills in constructing and validating protein structures that complements our work and they have demonstrated their commitment and expertise by achieving the demanding project objectives required by UCB. We look forward to continuing our relationship with Proteros."

As the drive for increased productivity within the pharmaceutical industry continues, technologies that can improve the success rates in the lead discovery and optimisation process remain a key focus. Over several years, protein crystallography has shown itself as one of these technologies. It is important as it allows scientists to directly visualize the three-dimensional structures and interactions of proteins, including enzymes, receptors and hormones. Being able to 'see' pharmacological interactions at the molecular level provides knowledge that enables structure-based drug design. Taking advantage of structural information and applying it in structure-based approaches to making new medicines promises to reduce the time and cost required to produce a medicine and deliver medicines that are more selective, potentially with fewer undesirable side effects.

Dr. Torsten Neuefeind, Proteros' Chief Executive Officer, commented, "It is a measure of the success and value of the work Proteros has performed over the last 4 years that UCB have chosen to expand the collaboration to include additional; high value targets. We look forward to continuing to contribute to UCB's success in the discovery of new medicines."

The research alliance between Proteros and UCB adds to UCB's open innovation model that aims to generate new knowledge and capitalize on external scientific advances, resources and expertise through dedicated collaborations that complement the company's unique internal capabilities and expertise.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Proteros Appoints Dr. Torsten Hoffmann as Chief Scientific Officer
Dr. Hoffmann will support the further growth of the Company’s Discovery business.
Tuesday, June 30, 2015
Proteros Achieves Key Milestone in Janssen Lead Discovery Collaboration
Company to discover potent and selective small molecule inhibitor series against a novel protein target.
Tuesday, May 19, 2015
Proteros Enters into a Collaboration with Bayer
Collaboration to develop new cardiovascular drug compounds for an integral membrane protein.
Saturday, January 10, 2015
Proteros Announces Changes in Management Team
The changes see a new Chief Financial Officer, and a promotion to Chief Operating Officer.
Monday, May 12, 2014
Proteros Elects New Supervisory Board Member
Shareholders confirmed the appointment of Prof. Eric-Paul Pâques as a new member of the Supervisory Board.
Thursday, February 20, 2014
Rodin Therapeutics Applies Insights of Epigenetics to Neurological Disorders
Founded by Atlas Venture and Proteros biostructures.
Monday, July 01, 2013
Proteros and Eisai Achieve Target in Lead Discovery Project
Companies delivering kinetically optimized lead compounds.
Tuesday, May 07, 2013
Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
Proteros biostructures GmbH announced they entered into a Lead Discovery Collaboration with Priaxon AG to jointly develop lead compounds for high value protein-protein interaction (PPI) drug targets.
Tuesday, April 09, 2013
Proteros Announces Successful Close of Financing Round
Largest-ever financing allows for expansion of drug discovery capabilities.
Tuesday, August 07, 2012
Proteros Appoints Dr Klaus Hinterding
Dr Klaus Hinterding, formerly at Hoffmann-La Roche Ltd, joins Proteros biostructures GmbH as Chief Scientific Officer and member of the management board.
Monday, February 13, 2012
Proteros Obtains CIR Accreditation
Accreditation allows eligible clients to receive 30% of their R&D costs in tax credits.
Wednesday, January 25, 2012
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, August 04, 2011
AMRI and Proteros Biostructures GmbH Announce Strategic Alliance
AMRI and Proteros Biostructures GmbH announces that they have signed an agreement for a joint offering to the life sciences industry.
Wednesday, July 20, 2011
Rigel and Proteros Renew X-ray Protein Crystallography Collaboration
Proteros will provide X-ray structure analysis of protein-compound complexes for specific targets to support Rigel’s discovery efforts.
Thursday, July 14, 2011
Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases
Proteros will apply its know-how, experience of structural analysis and proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.
Wednesday, May 25, 2011
Scientific News
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Advancing Cancer Drug Design with Image of Key Protein
Scientists have pioneered the use of a high-powered imaging technique to picture in exquisite detail one of the central proteins of life – a cellular recycling unit with a role in many diseases.
Mould Unlocks New Route to Biofuels
Scientists at The University of Manchester have made an important discovery that forms the basis for the development of new applications in biofuels and the sustainable manufacturing of chemicals.
'Invisible' Protein Structure Explains the Power of Enzymes
A research group at Umeå University in Sweden has managed to capture and describe a protein structure that, until now, has been impossible to study.
Unraveling the Elusive Structure of HIV Protein
Snapshots of HIV virus’ proteins may help design new ways to fight the disease.
Blueprinting Cell Membrane Proteins
Recent breakthrough will make the blueprinting process faster, easier and cheaper, and should have major implications in the field of drug discovery and development.
Bacteria Use Chemical Harpoons to Hold on Their Hosts
Researchers reveal how a common disease causing bacteria latches on to the body during an infection.
Solving Streptide from Structure to Biosynthesis
Researchers reveal new information about how bacteria communicate via the protein, streptide.
Near-Atomic Resolution of Protein Structure Holds Promise for Drug Discovery
A new study shows that it is possible to use an imaging technique called cryo-electron microscopy to view the architecture of a metabolic enzyme bound to a drug that blocks its activity.
X-ray Study May Aid in Designing Better Blood Pressure Drugs
New atomic-scale details could help create more effective medications with fewer side effects.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!